Ocugen Inc Stock Price, News & Analysis

Ocugen (NASDAQ: OCGN) announced the adjournment of its 2020 Annual Meeting to provide stockholders more time to vote on Item 2, which proposes amending its certificate of incorporation to reduce the authorized shares of common stock from 500 million to 400 million. The meeting will reconvene on January 13, 2021. Stockholders who have already voted do not need to vote again unless they wish to change their vote regarding Item 2. Voting for other items will remain open until December 23, 2020.

Ocugen (NASDAQ: OCGN) and Bharat Biotech have signed a binding LOI to co-develop the inactivated COVID-19 vaccine candidate, COVAXIN™, for the US market. This collaboration builds on promising Phase 1 and 2 trial results, which involved approximately 1,000 subjects in India. COVAXIN™ is currently in a Phase 3 trial with 26,000 volunteers. Ocugen will manage clinical development, registration, and commercialization in the US. The vaccine aims to provide broad immune coverage against COVID-19.

Ocugen, Inc. (NASDAQ: OCGN) has postponed its 2020 Annual Meeting of Stockholders to December 23, 2020, to allow more time for stockholders to vote on key proposals. The record date for eligible voters remains October 28, 2020. Stockholders who previously submitted proxies do not need to vote again, as their votes will still be valid. Stockholders are encouraged to cast their votes online or by phone before the meeting. The virtual meeting will begin at 11 a.m. Eastern time. For further details, stockholders can visit the company’s official website.

Ocugen, Inc. (NASDAQ: OCGN) will have its CEO, Dr. Shankar Musunuri, speak at Xconomy’s virtual event on December 3, 2020, discussing cell and gene therapies. The panel, moderated by Theresa Lavoie, will cover regulatory and reimbursement roadblocks facing the industry. Ocugen aims to develop transformative therapies for blindness diseases, utilizing a modifier gene therapy platform that treats multiple retinal diseases efficiently. Investors may find interest in the company's innovative approaches as they seek to address underserved diseases.

Ocugen, Inc. (NASDAQ: OCGN) reported its third quarter 2020 results, highlighting progress in its gene therapy developments.

The company is on track to initiate four Phase 1/2a trials in 2021-2022, specifically for its lead candidate OCU400. Ocugen raised approximately $28 million in 2020, enhancing its financial position.

As of September 30, 2020, cash reserves were $19.3 million, a significant increase from $7.6 million at year-end 2019. The company incurred a loss of $0.07 per share, markedly improving from a $3.55 loss per share in 2019.

Ocugen (NASDAQ: OCGN) will present at the Global Chinese Financial Forum Virtual Conference on November 5 at 1:45 PM ET. Dr. Shankar Musunuri, CEO, will discuss the company's innovative modifier gene therapy platform and lead product candidate, OCU400, which targets broad Retinitis Pigmentosa with four FDA orphan drug designations. The presentation will also cover Ocugen's partnership with CanSino Biologics for OCU400 in Greater China and the preclinical development of OCU200 for sight-threatening diseases. Registration for the conference is free.

Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, CEO and Co-Founder, will present on strategic partnerships in gene therapy at the 4th Annual Gene Therapy for Rare Disorders Europe Conference from October 26-28, 2020. His presentation, titled “The Importance of Strategic Partnerships in Gene Therapy,” is scheduled for October 28 at 11:00 AM GMT. Ocugen focuses on transformative therapies for blindness, leveraging its modifier gene therapy platform to address multiple retinal diseases.

Ocugen, Inc. (NASDAQ: OCGN) announced a Management Fireside Chat on October 21, 2020, at 11 a.m. ET, hosted by Cantor Fitzgerald. The discussion will feature key management figures, including Dr. Shankar Musunuri and Sanjay Subramanian, focusing on their lead program OCU400 for retinal degeneration disorders. The management will share clinical outcomes published in Nature Gene Therapy and updates on upcoming clinical trials. Cantor Fitzgerald has initiated coverage of Ocugen with an 'Overweight' rating and a $1.00 price target, highlighting the potential of AAV-based gene therapies.

Ocugen has announced an agreement with Kemwell Biopharma to manufacture OCU200, its biologic candidate for treating severe sight-threatening diseases. The collaboration aims to ensure product consistency for IND-enabling toxicology studies and Phase 1/2a clinical trials, targeting a clinic entry by 1H 2022. OCU200 addresses retinal diseases affecting over 9.5 million U.S. patients, with a unique mechanism compared to traditional therapies. This partnership is expected to facilitate the development of new treatments for patients who do not respond to existing therapies.